Piperacillin/tazobactam - NAEJA Pharmaceutical/Taiho Pharmaceutical
Alternative Names: Tazobac; Tazobactam/piperacillin; Tazobactam/piperacillin 1:8 ratio product; Tazocel; Tazocilline; Tazocin; YP-18; ZosynLatest Information Update: 05 Nov 2023
At a glance
- Originator NAEJA Pharmaceutical; Taiho Pharmaceutical
- Developer FUJIFILM Toyama Chemical; Taiho Pharmaceutical
- Class Anti-infectives; Antibacterials; Carboxylic acids; Penicillins; Piperazines
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Bacterial infections; Biliary tract infections; Cholangitis; Cholecystitis; Febrile neutropenia; Intra-abdominal infections; Nosocomial pneumonia; Peritonitis; Respiratory tract infections; Sepsis; Skin and soft tissue infections; Urinary tract infections